PMA for ultrasound breast lesion analysis is consistent with FDA policies -- ATL.
This article was originally published in The Gray Sheet
Executive Summary
PMA REQUIREMENT FOR ULTRASOUND TO DIFFERENTIATE BENIGN AND MALIGNANT breast lesions is supported by FDA policies and guidance documents, attorney Jeffrey Gibbs (Washington, D.C. firm Hyman, Phelps & McNamara) says in comments submitted to FDA on behalf of Advanced Technology Laboratories (ATL). Responding to a citizen's petition from Acuson which argued that differentiation between benign and malignant masses should be a 510(k) claim ("The Gray Sheet" June 12, I&W-4), Gibbs argued that "requiring a PMA...is consistent with long-standing policies. FDA has required PMAs for many devices that make cancer diagnostic claims, including claims relating to breast cancer."
You may also be interested in...
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.
Pipeline Watch: Five Approvals And 23 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.